A patient-based utility measure of health for clinical trials of cancer therapy based on the european organization for the research and treatment of cancer quality of life questionnaire

Value in Health

Volumn 12, Issue 6, 2009, Pages 977-988

  Pickard, A Simon ^a,b   Shaw, James W ^a   Lin, Hsiang Wen ^a   Trask, Peter C ^c   Aaronson, Neil ^d   Lee, Todd A ^a,b   Cella, David ^e,f  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Center for Outcomes Research and Education   (United States)

Author keywords

Cancer; EORTC QLQ C30; Preferences; Quality of life; Utility

Indexed keywords

ACCURACY; ADULT; ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CANCER PAIN; CANCER PATIENT; CANCER THERAPY; COLON CANCER; EUROPE; EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE 30; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEOPLASM; NONHODGKIN LYMPHOMA; ONCOLOGY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; STATISTICAL MODEL; SYMPTOM;

ACADEMIC MEDICAL CENTERS; ACTIVITIES OF DAILY LIVING; ADULT; AGED; ALGORITHMS; CLINICAL TRIALS AS TOPIC; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; SICKNESS IMPACT PROFILE; UNITED STATES;

EID: 67651211949     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00545.x     Document Type: Article

References (41)

1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993 85 : 365 76.
2. de Haes J, Curran D, Young T, et al. Quality of life evaluation in oncological clinical trials - the EORTC model. The EORTC Quality of Life Study Group. Eur J Cancer 2000 36 : 821 5.
3. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002 40 : 113 28.
4. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005 43 : 203 20.
5. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med 2001 33 : 337 43.
6. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 35 : 1095 108.
7. Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 2004 7 : 423 32.
8. Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005 23 : 515 26.
9. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 103 : 1644 51.
10. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004 8 : iii, ix xi, 1 82.
11. Lievens Y, Kesteloot K, van den Bogaert W. Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer. Int J Radiat Oncol Biol Phys 2005 63 : 1122 31.
12. Lievens Y, Kesteloot K, Van den Bogaert W. CHART in lung cancer: economic evaluation and incentives for implementation. Radiother Oncol 2005 75 : 171 8.
13. Warren E, Ward S, Gordois A, Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 2004 26 : 1924 33.
14. Bagust A, Barraza-Llorens M, Philips Z. Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials. Eur J Cancer 2001 37 : 1081 8.
15. Kind P. Measuring the value of quality of life in cancer: an index based on EORTC QLQC-30 (). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005 23 (16 Suppl. S6013.
16. Wu EQ, Mulani P, Farrell MH, et al. C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health 2007 10 : 408 14.
17. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993 118 : 622 9.
18. Guyatt GH, King DR, Feeny DH, et al. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999 52 : 187 92.
19. Dobrez D, Cella D, Pickard AS, et al. A. Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - general. Value Health 2007 10 : 266 72.
20. Aaronson NKA, Bergman B, Bullinger M, et al. The quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993 85 : 365 76.
21. Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 2000 17 : 151 65.
22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 92.
23. Brazier JE, Kolotkin RL, Crosby RD, Williams GR. Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D. Value Health 2004 7 : 490 8.
24. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004 42 : 851 9.
25. Keeney RL, Raiffa H. Decisions with Multiple Objectives: Preferences and Value Tradeoffs (2nd ed.). New York, NY : Cambridge University Press, 1993.
26. von Neumann J, Morgenstern O. Theory of Games and Economic Behavior (4th ed.). Princeton, NJ : Princeton University Press, 1944.
27. Stevens K, McCabe C, Brazier J, Roberts J. Multi-attribute utility function or statistical inference models: a comparison of health state valuation models using the HUI2 health state classification system. J Health Econ 2007 26 : 992 1002.
28. Shaw JW, Pickard AS, Lin H-W, et al. Evaluation of a theory of global health preference formation. Value Health 2008 11 : A14.
29. Nord E. The desirability of a condition versus the well being and worth of a person. Health Econ 2001 10 : 579 81.
30. Campbell A. Subjective measures of well-being. Am Psychol 1976 31 : 117 24.
31. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004 13 : 873 84.
32. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993 2 : 441 9.
33. Andrich D. A rating scale formulation for ordered response categories. Psychometrika 1978 43 : 56173.
34. Holzner B, Bode RK, Hahn EA, et al. Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer 2006 42 : 3169 77.
35. Wright BD, Mead RJ, Draba R. Detecting and Correcting Test Item Bias with a Logistic Response Model: Research Memorandum. Chicago, IL : MESA Press, 1976.
36. Wright BD, Linacre JM. Reasonable mean-square fit values. Rasch Meas Trans 1994 8 : 370.
37. Yager RR. Fusion of ordinal information using weighted median aggregation. Int J Approx Reason 1998 18 : 35 52.
38. Pickard AS, Wang Z, Walton SM, Lee TA. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? Health Qual Life Outcomes 2005 3 : 1 11.
39. Sengupta N, Nichol MB, Wu J, Globe D. Mapping the SF-12 to the HUI3 and VAS in a managed care population. Med Care 2004 42 : 927 37.
40. McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008 6 : 1 65.
41. Yu S-S, Shaw JW, Chen S-J, et al. A median model of U.S. EQ-5D health state preferences. Working paper presented at the 24th Plenary Meeting of the EuroQol Group, Kijkduin, The Netherlands, 2007.